Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...

Salk Institute researchers have identified a key protein that may help users of GLP-1 drugs such as Ozempic and Wegovy ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Glucagon-like peptide 1 receptor agonist use was not associated with an increased risk for thyroid cancer compared with use of dipeptidyl peptidase-4 inhibitors. HealthDay News — Glucagon-like peptide ...

Furthermore, the company’s broad obesity pipeline and the upcoming Phase 2 data for its lead GLP agonist, GSBR-1290, are expected to be major catalysts for the stock. The recent success of Novo ...

The company's lead candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist, has shown promising results in clinical trials for obesity and metabolic dysfunction-associated steatohepatitis ...

Atrial Flutter Market Outlook 2025-2035: The atrial flutter market is expected to exhibit a CAGR of 4.56% during 2025-2035. The atrial flutter market is growing as cardiovascular diseases become more ...

The once- and twice-daily GLP-1 RAs are now well established for ... It has similar efficacy to other GLP1 agonists, with seemingly lower incidence of nausea. Another important distinction to ...